Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P12E | ISIN: US55028X1090 | Ticker-Symbol: 4NX1
NASDAQ
28.03.24
19:25 Uhr
2,890 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
LUMOS PHARMA INC Chart 1 Jahr
5-Tage-Chart
LUMOS PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,6002,66028.03.

Aktuelle News zur LUMOS PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
20.03.LUMOS PHARMA, INC. - 8-K, Current Report1
20.03.Lumos Pharma, Inc.: Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 204245AUSTIN, Texas, March 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD)...
► Artikel lesen
08.03.Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript1
08.03.Earnings call: Lumos Pharma reports positive trial results for LUM-2012
08.03.Lumos Pharma Inc reports results for the quarter ended in December - Earnings Summary2
07.03.LUMOS PHARMA, INC. - 10-K, Annual Report1
07.03.LUMOS PHARMA, INC. - 8-K, Current Report1
07.03.Lumos Pharma: Q4 Earnings Insights1
07.03.Lumos Pharma, Inc.: Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update65End of Phase 2 Meeting to Occur in Q2 2024, Initiation of LUM-201 Phase 3 Trial Expected in Q4 2024 Previously Announced Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201...
► Artikel lesen
06.03.Lumos Pharma FY 2023 Earnings Preview1
06.03.Earnings Preview: Lumos Pharma1
26.02.Lumos Pharma, Inc.: Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 20241
05.02.Lumos Pharma, Inc.: Lumos Pharma to Participate in Oppenheimer's 34th Annual Healthcare Life Sciences Conference2
04.01.LUMOS PHARMA, INC. - 8-K, Current Report1
04.01.Lumos Pharma promotes Pisit Pitukcheewanont to chief medical officer1
04.01.Lumos Pharma, Inc.: Lumos Pharma Promotes Pisit "Duke" Pitukcheewanont, MD to Chief Medical Officer198AUSTIN, Texas, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, has promoted Pisit "Duke" Pitukcheewanont...
► Artikel lesen
21.11.23Lumos Pharma, Inc.: Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency1
20.11.23Lumos Pharma, Inc.: Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November1
15.11.23LUMOS PHARMA, INC. - 8-K, Current Report2
08.11.23Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?4
Seite:  Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1